Brain Metastasis of Triple‐Negative Breast Cancer: Mechanisms and Emerging Therapeutic Strategies
The Breast Journal · 2026-01 · 2026 (1)
DOI: 10.1155/tbj/5914207 ↗Abstract
Triple‐negative breast cancer (TNBC) is the most aggressive breast cancer subtype, and is characterized by an early metastatic tendency, marked biological heterogeneity, and poor clinical outcomes. Among all distant metastatic sites, the brain represents one of the most devastating locations, as brain metastasis is associated with substantial neurological morbidity, limited therapeutic options, and short survival. TNBC displays a disproportionate propensity for brain metastasis compared with hormone receptor‐positive disease, yet effective systemic treatment remains challenging because of the blood–brain barrier (BBB), the distinct brain tumor microenvironment (TME), and the absence of broadly applicable molecular targets. In this review, we summarize the molecular basis of TNBC brain metastasis with an emphasis on four major aspects: tumor microenvironmental remodeling, BBB interaction, oncogenic signaling pathways, and metabolic reprogramming. We discuss how reactive astrocytes, microglia, inflammatory cytokines, and tumor‐intrinsic programs collectively facilitate brain colonization and therapeutic resistance. In addition, we review current and emerging treatment strategies, including chemotherapy, antibody–drug conjugates, targeted therapy, immunotherapy, and novel drug‐delivery systems. Particular attention is given to the translational gap between preclinical promise and clinical benefit, the frequent exclusion of patients with active brain metastases from clinical trials, and the need for more rigorous intracranial efficacy assessment. A better understanding of the dynamic interaction between TNBC cells and the brain niche may support the development of more effective and biologically informed therapeutic strategies for this high‐risk population.
EUVIMED